EA200200234A1 - PREPARATIONS FOR PARENTERAL APPLICATION OF ESTRAMUSTINES OF PHOSPHATE AND ALBUMIN - Google Patents

PREPARATIONS FOR PARENTERAL APPLICATION OF ESTRAMUSTINES OF PHOSPHATE AND ALBUMIN

Info

Publication number
EA200200234A1
EA200200234A1 EA200200234A EA200200234A EA200200234A1 EA 200200234 A1 EA200200234 A1 EA 200200234A1 EA 200200234 A EA200200234 A EA 200200234A EA 200200234 A EA200200234 A EA 200200234A EA 200200234 A1 EA200200234 A1 EA 200200234A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phosphate
albumin
estramustine phosphate
estramustines
preparations
Prior art date
Application number
EA200200234A
Other languages
Russian (ru)
Inventor
Лорена Муджетти
Паоло Коломбо
Алессандро Мартини
Джованни Буцци
Original Assignee
Фармация Энд Апджон С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9918779.1A external-priority patent/GB9918779D0/en
Priority claimed from IT1999MI001998 external-priority patent/IT1313629B1/en
Application filed by Фармация Энд Апджон С.П.А. filed Critical Фармация Энд Апджон С.П.А.
Publication of EA200200234A1 publication Critical patent/EA200200234A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предложен фармацевтический препарат, который содержит парентерально приемлемый носитель или разбавитель и эстрамустин фосфат в смеси с человеческим альбумином, где массовое отношение эстрамустин фосфата и человеческого альбумина составляет приблизительно от 1:5 до 1:0,3. Препарат может быть введен в соответствии с комбинированной химиотерапевтической схемой приема лекарства в сочетании с одним или несколькими химиотерапевтическими агентами. Препарат также обеспечивает возможность введения эстрамустин фосфата без побочных эффектов на участке инъекции.Отчет о международном поиске был опубликован 2001.05.25.A pharmaceutical preparation is proposed which contains a parenterally acceptable carrier or diluent and estramustine phosphate in admixture with human albumin, where the mass ratio of estramustine phosphate and human albumin is from about 1: 5 to 1: 0.3. The drug can be administered in accordance with the combined chemotherapeutic regimen of medication in combination with one or more chemotherapeutic agents. The drug also provides the possibility of introducing estramustine phosphate without side effects at the injection site. The international search report was published on 2001.05.25.

EA200200234A 1999-08-09 2000-08-03 PREPARATIONS FOR PARENTERAL APPLICATION OF ESTRAMUSTINES OF PHOSPHATE AND ALBUMIN EA200200234A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9918779.1A GB9918779D0 (en) 1999-08-09 1999-08-09 Formulations for parenteral use of estramustine phosphate and albumin
IT1999MI001998 IT1313629B1 (en) 1999-09-27 1999-09-27 New pharmaceutical compositions comprising estramustine phosphate and human albumin, useful for treating cancer e.g. prostate, breast, lung, pancreatic, colorectal, ovarian or brain cancer or melanoma
PCT/EP2000/007678 WO2001010446A2 (en) 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin

Publications (1)

Publication Number Publication Date
EA200200234A1 true EA200200234A1 (en) 2002-06-27

Family

ID=26315835

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200234A EA200200234A1 (en) 1999-08-09 2000-08-03 PREPARATIONS FOR PARENTERAL APPLICATION OF ESTRAMUSTINES OF PHOSPHATE AND ALBUMIN

Country Status (17)

Country Link
EP (1) EP1206266A2 (en)
JP (1) JP2003506408A (en)
KR (1) KR20020019967A (en)
CN (1) CN1511037A (en)
AU (1) AU6280900A (en)
BR (1) BR0013276A (en)
CA (1) CA2380312A1 (en)
CZ (1) CZ2002376A3 (en)
EA (1) EA200200234A1 (en)
HU (1) HUP0202645A3 (en)
IL (1) IL147745A0 (en)
MX (1) MXPA02001395A (en)
NO (1) NO20020631L (en)
NZ (1) NZ517632A (en)
PL (1) PL353406A1 (en)
SK (1) SK1782002A3 (en)
WO (1) WO2001010446A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100426450B1 (en) * 2002-03-16 2004-04-13 박래옥 Anticancer Composition Comprising Citric acid, Albumin And Zinc
SI1585548T1 (en) * 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
BRPI0408978B8 (en) 2003-04-08 2021-07-27 Novo Nordisk As processes for regenerating a chromatographic stationary phase
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
DE102006024528A1 (en) * 2006-05-23 2007-11-29 Albupharm Heidelberg Gmbh & Co. Kg New formulation of a cytostatic, especially cis-platin, oriented on tumor physiology

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59108800A (en) * 1982-12-13 1984-06-23 Japan Atom Energy Res Inst Fine particle having guided missile action and slow-releasing function of carcinostatic agent
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same

Also Published As

Publication number Publication date
NO20020631D0 (en) 2002-02-08
HUP0202645A3 (en) 2004-06-28
SK1782002A3 (en) 2002-05-09
NZ517632A (en) 2004-02-27
WO2001010446A2 (en) 2001-02-15
WO2001010446A3 (en) 2001-05-25
HUP0202645A2 (en) 2002-12-28
BR0013276A (en) 2004-08-03
IL147745A0 (en) 2002-08-14
CZ2002376A3 (en) 2002-06-12
KR20020019967A (en) 2002-03-13
JP2003506408A (en) 2003-02-18
MXPA02001395A (en) 2002-08-12
NO20020631L (en) 2002-02-08
CA2380312A1 (en) 2001-02-15
PL353406A1 (en) 2003-11-17
CN1511037A (en) 2004-07-07
AU6280900A (en) 2001-03-05
EP1206266A2 (en) 2002-05-22

Similar Documents

Publication Publication Date Title
BR9912694A (en) Compound to prepare pulmonary administration medication
RU94033520A (en) Injected lecithin gel
GR862316B (en) Emulsion compositions for administation of sparingly water soluble ionizable hydrophobic drugs
MXPA02007932A (en) Nucleoside analogs with carboxamidine modified bicyclic base.
ATE92080T1 (en) ISOLATION AND STRUCTURE DETERMINATION OF THE CYTOSTATIC LINEAR DEPSIPEPTIDE DOLASTATIN 15.
KR910000703A (en) Antagonists of Tetrazol Stimulating Amino Acid Receptors
DE69804974D1 (en) OPIOID CONJUGATES WITH ENDOGENIC CARRIER PROTEINS
EA200200119A1 (en) β-CARBOLINE DRUGS
MY139203A (en) Pharmaceutical composition
MY113203A (en) Lyophilizate of lipid complex of water insoluble camptothecins
PT1007055E (en) UTILIZATION OF AMIFOSTINE
EA200200368A1 (en) PREPARATIONS FOR PARENTERAL APPLICATION OF ESTRAMUSTINE PHOSPHATE AND AMINO ACIDS
EA200200234A1 (en) PREPARATIONS FOR PARENTERAL APPLICATION OF ESTRAMUSTINES OF PHOSPHATE AND ALBUMIN
ATE272648T1 (en) GLYCOCONJUGATES OF 20(S)-CAMPTOTHECINE
BR9710377A (en) Orally administered hexahydropyrazine derivatives granules
ES2086195T3 (en) NEW DERIVATIVES PSEUDOPEPTIDICOS OF ANTAGONIST ACTIVITY OF BRADIQUININA, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ATE296115T1 (en) SITE-SPECIFIC DRUG ADMINISTRATION
BR0107630A (en) Composition
GB0018322D0 (en) Pharmaceutical compositions
EA200200369A1 (en) PREPARATIONS OF ESTRAMOSTINPHOSPHATE FOR PARENTERAL APPLICATION WITH IMPROVED PHARMACOLOGICAL PROPERTIES
SE8804640D0 (en) MEDICAMENT COMPRISING CYCLOLINOPEPTIDE A
TR200000728T2 (en) The use of IFN-alpha and amantadine in the treatment of chronic hepatitis C.
SE9904132D0 (en) Pharmaceutical composition for treatment of diarrhea
Finkler et al. Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer.
DE69011692D1 (en) THERAPEUTIC AGENTS.